Peripheral blood immunosuppressive myeloid phenotype in NHL patients is limited to CD14⁺HLA-DR^−/low. There were no statistically significant differences between controls and lymphoma for MDSCs (A) (MDSCs: control, n = 20; lymphoma, n = 40) or CD16⁺ monocytes (B) (control, n = 20; lymphoma, n = 40). (C) CD14⁺HLA-DR⁻ population of monocytes were phenotypically distinct from MDSCs in that they were lineage⁺ and were not representative of nonclassic monocytes in that they are CD16⁻. (D) Circulating Tregs were not elevated in lymphoma patients. Absolute count of Tregs and CD4 T cells in peripheral blood was analyzed with TruCount flow cytometry tubes. Percentage of Tregs within CD4 T-cell population is processed and analyzed by standard immunofluorescent flow cytometry. Lymphoma patients had decreased absolute circulating Treg count (top panel: control, n = 23; lymphoma, n = 28). This is reflective of a decrease in absolute CD4 T-cell count in lymphoma (middle panel: control, n = 25; lymphoma, n = 28) as the percentage of Tregs in CD4 T-cell population is not different compared with control (bottom panel: control, n = 23; lymphoma, n = 28). (E) Plasma concentration of IL-6 (top panel: control, n = 6; lymphoma, n = 26) and IL-10 (middle panel: control, n = 6; lymphoma, n = 25) were measured by ELISA. VEGF concentration was elevated in lymphoma patients but not correlated to CD14⁺HLA-DR⁻ monocytes. Plasma VEGF concentration was measured by ELISA (bottom panel: control, n = 5; lymphoma, n = 19). Lymphoma VEGF concentration did not correlate with the presence of CD14⁺HLA-DR⁻ monocytes (data not shown). Statistically significant P values are shown between the groups. NS indicates that P value was not significant.